Similar to ICAM-1, the increased FGG expression was also associated with worse long-term progression-free and overall survival outcomes in NSCLC patients according to Kaplan-Meier estimate (Supplementary Fig. S5A). The gene discussed is FGG; the disease is non-small cell lung carcinoma.